← Back to Screener
Grace Therapeutics, Inc. Common Stock (GRCE)
Price$4.59
Favorite Metrics
Price vs S&P 500 (26W)45.10%
Price vs S&P 500 (4W)-5.42%
Market Capitalization$71.03M
All Metrics
Book Value / Share (Quarterly)$4.19
P/TBV (Annual)1.23x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.54
Price vs S&P 500 (YTD)28.81%
Gross Margin (TTM)65.00%
Net Profit Margin (TTM)-4435.00%
EPS (TTM)$-0.36
10-Day Avg Trading Volume1.32M
EPS Excl Extra (TTM)$-0.36
EPS (Annual)$-1.35
ROI (Annual)-20.82%
Gross Margin (Annual)60.00%
Net Profit Margin (5Y Avg)-5595.44%
Cash / Share (Quarterly)$1.21
ROA (Last FY)-17.53%
EBITD / Share (TTM)$-0.72
ROE (5Y Avg)-64.77%
Operating Margin (TTM)-2130.00%
Cash Flow / Share (Annual)$-1.09
P/B Ratio1.09x
P/B Ratio (Quarterly)0.83x
Net Income / Employee (Annual)$-0
Net Interest Coverage (TTM)-7.01x
ROA (TTM)-3.79%
EPS Incl Extra (Annual)$-1.35
Current Ratio (Annual)11.77x
Quick Ratio (Quarterly)14.56x
3-Month Avg Trading Volume0.35M
52-Week Price Return125.49%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.54
P/S Ratio (Annual)355.13x
Asset Turnover (Annual)0.00x
52-Week High$5.18
Operating Margin (5Y Avg)-5314.69%
EPS Excl Extra (Annual)$-1.35
26-Week Price Return53.85%
Quick Ratio (Annual)11.53x
13-Week Price Return26.37%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.96x
Enterprise Value$52.354
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.40x
Pretax Margin (Annual)-9840.00%
Cash / Share (Annual)$1.61
3-Month Return Std Dev78.64%
Gross Margin (5Y Avg)67.56%
Net Income / Employee (TTM)$-0
ROE (Last FY)-20.82%
Net Interest Coverage (Annual)-5.12x
EPS Basic Excl Extra (Annual)$-1.35
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.36
Receivables Turnover (Annual)1.60x
ROI (TTM)-4.04%
P/S Ratio (TTM)355.13x
Pretax Margin (5Y Avg)-5595.44%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.86
Price vs S&P 500 (52W)90.40%
Year-to-Date Return32.95%
5-Day Price Return20.42%
EPS Normalized (Annual)$-1.35
ROA (5Y Avg)-44.34%
Net Profit Margin (Annual)-9840.00%
Month-to-Date Return-0.65%
EBITD / Share (Annual)$-1.34
Operating Margin (Annual)-8210.00%
LT Debt / Equity (Annual)0.20x
ROI (5Y Avg)-64.77%
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$-0.36
P/TBV (Quarterly)2.25x
P/B Ratio (Annual)0.47x
Inventory Turnover (TTM)1.00x
Pretax Margin (TTM)-4435.00%
Book Value / Share (Annual)$4.86
Price vs S&P 500 (13W)23.51%
Beta0.69x
Revenue / Share (TTM)$0.00
ROE (TTM)-4.04%
52-Week Low$2.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GRCEGrace Therapeutics, Inc. Common Stock | 355.13x | — | 65.00% | — | $4.59 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Grace Therapeutics is a specialty pharmaceutical company developing drug delivery technologies for rare and orphan diseases. Its lead program, GTx-104, is a novel injectable nimodipine formulation in late-stage development for aneurysmal subarachnoid hemorrhage. The company's pipeline includes additional candidates targeting ataxia-telangiectasia, postherpetic neuralgia, and other rare disease indications.